Navigation Links
Oncothyreon to receive milestone payment
Date:5/14/2008

uture prospects, this release contains statements that are forward looking, including statements related to payments Oncothyreon may expect to receive; the therapeutic and commercial potential of Stimuvax; future clinical development plans; the details of clinical trials; and the anticipated future size of the market for Stimuvax. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of Stimuvax, and the possibility of future milestone and royalty payments. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed by Oncothyreon I
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon Reports First Quarter 2008 Financial Results
2. Oncothyreon files investigational new drug application for PX-866 oncology compound
3. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
4. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
5. Oncothyreon announces effectiveness of shelf registration statement
6. Oncothyreon announces issuance of patent for PX-867
7. Oncothyreon to present at upcoming investment conferences
8. Oncothyreon reports full year and fourth quarter 2007 financial results
9. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
10. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
11. Oncothyreon launches new corporate website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... Fla., April 9 Cryo-Cell International, Inc. ... world,s largest and most established family cord blood banks, ... 28, 2009. Consolidated revenues for the first quarter ... approximately $4.2 million for the first quarter of fiscal ...
... the release of it,s advanced nutritional supplement, Caplex, ... a unique patent pending formulation created by ... provides cancer patients a comprehensive source of the ... on results accumulated from medical research. Impressive changes ...
... NANTONG, China, April 8 Sinobiopharma Pharmaceutical Group ... the appointment of Ms. Yan Tan as Director ... Co., Ltd., Netherlands. She served as a China-based ... sold to Schering-Plough. Prior to Organon, Ms. Tan ...
Cached Biology Technology:Cryo-Cell International, Inc. Reports First Quarter 2009 Results 2Cryo-Cell International, Inc. Reports First Quarter 2009 Results 3Cryo-Cell International, Inc. Reports First Quarter 2009 Results 4Cancer Fighting Nutrition Supplement, Caplex, Offers Cancer Patients A New All-Natural Treatment Option 2Sinobiopharma, Inc. Appoints New Director of Marketing 2
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... Of Southern California School Of Dentistry have uncovered another clue ... leads to palate formation. Cleft palate is one ... out of every 700 live births. Clefts are more common ... males are twice as likely to have a cleft lip, ...
... record biometric revenues and profitability, WALL, N.J., ... BKYI), a leader in wireless public safety and,finger-based ... and strong revenue growth for its second quarter,ended ... operations for the quarter ended June 30,2008 was ...
... As people age, their cells become less efficient at ... of toxic material that is especially pronounced in Alzheimer,s, Parkinson,s ... first time, scientists at the Albert Einstein College of Medicine ... entire organ the liver and shown that, as ...
Cached Biology News:USC researchers identify alternate pathway that leads to palate development 2USC researchers identify alternate pathway that leads to palate development 3BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 3BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 4BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 5In scientific first, Einstein researchers correct decline in organ function associated with old age 2In scientific first, Einstein researchers correct decline in organ function associated with old age 3
Request Info...
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Competitors to lower non-specific signal...
Biology Products: